澳大利亚基于mRNA的COVID-19加强针接种高效且具成本效益
研究采用决策分析马尔可夫模型,从医疗体系角度评估澳大利亚2021年11月起对≥16岁人群在第二剂后3个月接种mRNA加强针的策略在180天内的成本效益。与不接种加强针相比,该策略可节省净成本并增加质量调整生命年,且能减少感染、住院、ICU入住和死亡。
要点
- 与不接种加强针相比,加强针策略在180天内净节省A$0.43亿,效益成本比为1.45。
核心结论
- 澳大利亚实施的COVID-19加强针策略对Omicron疫情可能有效且具成本效益,普遍接种加强针可进一步改善其效果和成本效益。
研究设计与样本
- 研究构建了COVID-19决策分析马尔可夫模型,从医疗体系角度评估在≥16岁人群中第二剂后3个月接种加强针策略的成本效益,支付意愿阈值选为A$50,000,时间范围为180天。
主要发现
- 与不接种加强针相比,加强针策略额外花费A$0.88亿,但节省直接医疗成本A$1.28亿,并获得670个质量调整生命年(QALYs)。
- 该策略净货币效益为A$0.43亿,效益成本比为1.45。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Australia implemented an mRNA-based booster vaccination strategy against the COVID-19 Omicron variant in November 2021. We aimed to evaluate the effectiveness and cost-effectiveness of the booster strategy over 180 days. METHODS: We developed a decision-analytic Markov model of COVID-19 to evaluate the cost-effectiveness of a booster strategy (administered 3 months after 2nd dose) in those aged ≥ 16 years, from a healthcare system perspective. The willingness-to-pay threshold was chosen as A$ 50,000. RESULTS: Compared with 2-doses of COVID-19 vaccines without a booster, Australia's booster strategy would incur an additional cost of A$0.88 billion but save A$1.28 billion in direct medical cost and gain 670 quality-adjusted life years (QALYs) in 180 days of its implementation. This suggested the booster strategy is cost-saving, corresponding to a benefit-cost ratio of 1.45 and a net monetary benefit of A$0.43 billion. The strategy would prevent 1.32 million new infections, 65,170 hospitalisations, 6,927 ICU admissions and 1,348 deaths from COVID-19 in 180 days. Further, a universal booster strategy of having all individuals vaccinated with the booster shot immediately once their eligibility is met would have resulted in a gain of 1,599 QALYs, a net monetary benefit of A$1.46 billion and a benefit-cost ratio of 1.95 in 180 days. CONCLUSION: The COVID-19 booster strategy implemented in Australia is likely to be effective and cost-effective for the Omicron epidemic. Universal booster vaccination would have further improved its effectiveness and cost-effectiveness.
引用
- Li R, Liu H, Fairley CK, et al. mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia. Vaccine. 2023. PMID: 36781332. doi:10.1016/j.vaccine.2023.01.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。